Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06925464 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas

Name: CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas — clinical trial record (NCT06925464)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1/2

SponsorBeijing GoBroad Hospital

Started2025-04-01

View on ClinicalTrials.gov ↗

Record status

This record was last updated May 13, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2025-05-11

Study Status, Contacts/Locations v1

Study sites3→4

2025-04-06

Original filing

Beijing GoBroad Hospital

35 trials monitored

See 2 trials at risk

Non-Hodgkin Lymphoma

1,512 trials monitored

See 79 trials at risk

This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD7 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD7 CAR T cell bridging to HSCT in the treatment of r/r T-NHL. The primary endpoint is the type and incidence of dose limiting toxicity (DLT) within 21 days after CD7 CAR-T cell infusion. A total of 36 subjects is estimated to be enrolled.

Trial Details

NCT Number	NCT06925464
Lead Sponsor	Beijing GoBroad Hospital Collaborators: Ruijin Hospital, Shanghai Liquan Hospital
Conditions	T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)
Enrollment	36 participants
Start Date	2025-04-01
Primary Completion	2026-04-01 (estimated)
Study Completion	2027-04-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-13